Design, fabrication and evaluation of physical and chemical properties and evaluation of the clinical effect of formulation of targeted cerebral drug delivery system through the nose containing Sumatriptan in acute migraine attacks
Phase 3
- Conditions
- Acute migraine attack.Migraine
- Registration Number
- IRCT20180120038450N4
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 73
Inclusion Criteria
Patients with 2 to 8 migraine attacks per month
History of more than one year with migraine(with aura or without aura)
Exclusion Criteria
Pregnancy
History of high blood pressure
History of myocardial infarction
History of stroke
Allergy to sumatriptan
History of coronary artery disease
History of congenital heart disease
Cardiovascular disease
Pulmonary disease
Cardiac arrhythmias
Angina
Cerebrovascular disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Migraine headache condition. Timepoint: Before the intervention and a month later. Method of measurement: Visual Analogue Scale/Headache Impact Test.
- Secondary Outcome Measures
Name Time Method Adverse effect. Timepoint: At the onset of a migraine attack up to two hours after taking the drug. Method of measurement: Side effects questionnaire.